Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial

The Lancet HIV 2026

View at publisher
Authors: Juergen Rockstroh, Sheetal Kassim, Roger Paredes, Christopher Bettacchi, Gary I Sinclair, Anchalee Avihingsanon, Nelly Mugo, Jean-Michel Molina, Brenda Crabtree Ramírez, Hiroyuki Gatanaga, Yayun Xu, Stephanie O. Klopfer
+5 more Tracy L. Diamond, Mary Vesnesky, Luisa M. Stamm, Michelle C Fox, Mary L. Pisculli
DOI: 10.1016/s2352-3018(26)00033-0
Cited by: 9
References: 18

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV-related health complications and treatments HIV/AIDS Research and Interventions

Publication details

Journal / source
The Lancet HIV
Publisher
Elsevier BV
Volume
13
Issue
7
Pages
e440–e451
Publication date
25 February 2026
Language
EN